Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.
about
Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antiviralsFrequent Recovery and Broad Genotype 2 Diversity Characterize Hepatitis C Virus Infection in Ghana, West AfricaHepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patientsIncreased hepatitis C virus (HCV)-specific CD4+CD25 + regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levelsPathological evolution of hepatitis C virus-“Healthy carriers”Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis CDiagnosis, management, and treatment of hepatitis C: an updateNatural history of chronic hepatitis CSteroid-refractory chronic idiopathic thrombocytopenic purpura associated with hepatitis C virus infection.Histological and clinical characteristics of patients with chronic hepatitis C and persistently normal alanine aminotransferase levelsNormal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort studyShould patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort.Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection.Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.Hepatitis C advances in antiviral therapy: what is accepted treatment now?Pathogenesis of hepatitis C virus recurrence in the liver allograft.Fibrosis and disease progression in hepatitis C.Noninvasive monitoring of patients with chronic hepatitis C.The role of liver biopsy in chronic hepatitis C.Treatment of patients with hepatitis C and normal serum aminotransferase levels.Dysfunction of Immune Systems and Host Genetic Factors in Hepatitis C Virus Infection with Persistent Normal ALT.The history of the "natural history" of hepatitis C (1968-2009).The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experienceThe impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection.Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases.Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma.Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.Detection of liver disease in injection drug users.Should we treat HCV carriers with normal ALT levels? The '5Ws' dilemma.Public health impact of antiviral therapy for hepatitis C in the United States.Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.Optimum predictors of therapeutic outcome in HCV patients in Pakistan.Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up.Patients with chronic hepatitis C and normal transaminases.Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years.Hepatitis C infection in Alaska Natives with persistently normal, persistently elevated or fluctuating alanine aminotransferase levels.Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels.
P2860
Q26782033-FB9C6B56-901B-4660-B964-82BB651D211CQ27477557-736B5CB1-3142-4E6B-AB88-11FA44135F80Q27477975-7128B40B-495C-4A48-9EE5-6E9E173E7C2BQ27478131-4BE62BFD-0B78-4FBE-9A05-AE0E2BD2D971Q27489097-D8AE3D42-A09D-439F-B958-5FB76B2EAE6AQ28539814-2C7FFF2D-CAAE-4233-A6BD-737556522D12Q29619682-178BEFA0-286B-4A06-AB8C-E5376DCE4EEEQ29620673-389B7279-AE95-4001-A18C-5E7DFB16F728Q33341932-00ED7052-66D1-4AEB-9B8D-ACEFFF6A05B9Q33660486-2C98BF49-19A9-4957-8754-625A09C3F989Q33709267-A1828B1A-37E2-45B3-818A-C4F394AC0DF6Q33836312-A5BC72E7-8861-4C99-A5A2-F62F4FE154CEQ34186933-BE041AEB-2648-4695-8AC0-6E292B9545FEQ34276469-8A6B1F0F-BCDE-4290-9C62-CEBA335B2C57Q34619384-16905D71-02B9-4F16-84B8-EBF47BEA3FA5Q34936128-1C88C367-2649-4C02-A129-735A1AE712BEQ34984040-9212AE27-6C06-4286-82B8-3F1ABC9C7E98Q34984046-FAE36F8F-19B1-4E0B-BDD3-68FBE276A438Q34984093-159984A5-8372-43A2-BF9F-C25DCD5936C3Q34984108-CD2081A9-942D-4AA0-830F-52A432B00E90Q35094287-512F413C-44F5-46EE-B8E0-15846A7C33F4Q35216592-11095BAE-F652-4363-8996-4057972838AAQ35495205-11D55801-DF85-429C-B3A2-59284FFC4014Q35590977-EBF16E35-CADA-499F-9185-1BCDD41CCBC6Q35596078-02D61292-4648-45F7-8707-1D38467A102AQ36609890-D067FDDD-3F48-47AA-9F08-C767C015FD48Q37028389-66CA633E-517E-4D6E-9C22-C98D7F2D8D9DQ37155215-E6706B76-1B55-43F4-94AC-319EAE86C6A9Q37235525-0C460776-08FD-490D-88C7-8B8C3FD5E8F1Q37992183-B3CE966D-AA84-4D3A-9501-69A90A806012Q39939298-E689EBF8-5EF8-4097-A96B-C5E5926E6775Q40279001-7340B7F0-F9E1-41B1-AC59-2602AC6E938EQ40454523-35340D82-A512-4335-9345-1C4D8E3D0B47Q41143949-DEC8A456-8A09-404E-A5AD-356643776145Q42225908-C45E3C01-59DF-4D78-BF2D-D36629DB73CFQ42271121-39D1596B-71BA-4203-BFD0-2C1A6C6BF4F5Q42996773-6FBF086E-D6B9-42B0-9666-E20C2F3C4DDFQ42999748-50A406E4-D393-4C10-A5FF-AEFF299EAE0DQ43001259-370DCA96-C069-4836-8D4B-FA94026B5E05Q43034283-3A4E21FB-59E4-430B-8883-368708F64B2F
P2860
Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Natural history of hepatitis C ...... ormal aminotransferase levels.
@en
Natural history of hepatitis C ...... ormal aminotransferase levels.
@nl
type
label
Natural history of hepatitis C ...... ormal aminotransferase levels.
@en
Natural history of hepatitis C ...... ormal aminotransferase levels.
@nl
prefLabel
Natural history of hepatitis C ...... ormal aminotransferase levels.
@en
Natural history of hepatitis C ...... ormal aminotransferase levels.
@nl
P2093
P1433
P1476
Natural history of hepatitis C ...... normal aminotransferase levels
@en
P2093
B Palmentieri
P304
P356
10.1016/S0016-5085(00)70145-4
P407
P577
2000-04-01T00:00:00Z